B of A Securities Maintains Neutral on 10x Genomics, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Derik De Bruin maintains a Neutral rating on 10x Genomics (NASDAQ:TXG) but lowers the price target from $36 to $25.
July 18, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities has maintained a Neutral rating on 10x Genomics but has lowered the price target from $36 to $25, indicating a less optimistic outlook.
The lowered price target from $36 to $25 by B of A Securities suggests a less optimistic outlook for 10x Genomics. This could lead to a negative short-term impact on the stock price as investors may adjust their expectations accordingly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100